Patients were given aztreonam (SQ 26,776) parenterally for the treatment of various gram-negative infections. During or shortly after therapy, 8 (17.8%) of 45 patients became infected with or colonized by enterococcus. These eight cases included eight urinary tract isolates; one of these cases subsequently developed bacteremia. Five patients required further antimicrobial therapy directed against enterococcus. Patients receiving aztreonam are at risk for the development of enterococcal superinfection or colonization.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC284140 | PMC |
| http://dx.doi.org/10.1128/AAC.26.2.280 | DOI Listing |
Publication Analysis
Top Keywords
enterococcal superinfection
8
superinfection colonization
8
colonization aztreonam
4
aztreonam therapy
4
patients
4
therapy patients
4
patients aztreonam
4
aztreonam 26776
4
26776 parenterally
4
parenterally treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!